Literature DB >> 8761851

Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.

R Yang1, G R Thomas, S Bunting, A Ko, N Ferrara, B Keyt, J Ross, H Jin.   

Abstract

Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, has therapeutic benefit in animal models of coronary or limb ischemia. However, the hemodynamic effects of VEGF have not been investigated. We examined the effects of VEGF on hemodynamics and cardiac performance. Mean arterial pressure (MAP), heart rate (HR), cardiac output, stroke volume, left ventricular (LV) dP/dt, and hematocrit were measured before and after intravenous injection of VEGF in conscious, instrumented rats. VEGF caused a dose-dependent reduction in MAP and an associated increase in HR. VEGF (250 micrograms/kg) significantly decreased cardiac output and stroke volume without affecting the inotropic state of the left ventricle, as determined by dP/dt. VEGF significantly increased hematocrit. Furthermore, VEGF did not affect contractility or HR in the isolated rat heart in vitro. The data suggest that the VEGF-induced decrease in cardiac output is due to reduced stroke volume, which may be caused by a decrease in venous return rather than a direct effect on myocardial contractility. In addition, pretreatment with N omega-nitro-L-arginine methyl-ester (L-NAME), a nitric oxide (NO) synthase inhibitor, significantly attenuated the depressor and tachycardic responses to VEGF, suggesting that VEGF-induced hypotension may be mediated by NO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761851     DOI: 10.1097/00005344-199606000-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  54 in total

1.  Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.

Authors:  Louisa Bokacheva; Khushali Kotedia; Megan Reese; Sally-Ann Ricketts; Jane Halliday; Carl H Le; Jason A Koutcher; Sean Carlin
Journal:  NMR Biomed       Date:  2012-07-08       Impact factor: 4.044

Review 2.  The Key Role of the Blood Supply to Bone.

Authors:  Massimo Marenzana; Timothy R Arnett
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

3.  Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study.

Authors:  Focke Ziemssen; Qi Zhu; Swaantje Peters; Salvatore Grisanti; Mohammed El Wardani; Peter Szurman; Karl U Bartz-Schmidt; Tjalf Ziemssen
Journal:  Int Ophthalmol       Date:  2008-04-17       Impact factor: 2.031

Review 4.  Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?

Authors:  A R L Medford; A B Millar
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

5.  Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration.

Authors:  A Sengul; R Rasier; C Ciftci; O Artunay; A Kockar; H Bahcecioglu; E Yuzbasioglu
Journal:  Eye (Lond)       Date:  2017-01-06       Impact factor: 3.775

6.  The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Authors:  M Skinner; K Philp; D Lengel; L Coverley; E Lamm Bergström; P Glaves; H Musgrove; H Prior; M Braddock; R Huby; J O Curwen; P Duffy; A R Harmer
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 7.  Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer.

Authors:  Muhammad Wasif Saif; Valerie Relias; Kostas Syrigos; Krishna S Gunturu
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.

Authors:  H-T Tsai; J L Marshall; S R Weiss; C-Y Huang; J L Warren; A N Freedman; A Z Fu; L B Sansbury; A L Potosky
Journal:  Ann Oncol       Date:  2013-02-20       Impact factor: 32.976

9.  Spatiotemporal control of vascular endothelial growth factor expression using a heat-shock-activated, rapamycin-dependent gene switch.

Authors:  Francisco M Martín-Saavedra; Christopher G Wilson; Richard Voellmy; Nuria Vilaboa; Renny T Franceschi
Journal:  Hum Gene Ther Methods       Date:  2013-05-06       Impact factor: 2.396

Review 10.  Vascular endothelial growth factors and vascular permeability.

Authors:  David O Bates
Journal:  Cardiovasc Res       Date:  2010-04-16       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.